Hyponatremia induced by post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation

Marta Gómez-Hernando¹, Luis F Quintana^{2

3

4}, María Suárez-Lledo^{1

3}, Nuria Martínez-Cibrian^{1

3}, Andrea Rivero^{1

3}, Sonia Ruiz-Boy⁵, Ester Carcelero⁵, Paula Mate⁵, Gisela Riu⁵, Inés Monge⁵, Anna Serrahima¹, Maria Teresa Solano¹, Laura Rosiñol^{1

3

4}, Jordi Esteve^{1

3

4}, Alvaro Urbano-Ispizua^{1

3

4}, Enric Carreras⁶, Francesc Fernández-Avilés^{1

4}, Carmen Martínez^{1

3

4}, Montserrat Rovira^{1

3

4}, Maria Queralt Salas^{7

8}

Affiliations

¹ Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.
² Clinical Nephrology Section, Nephrology and Renal Transplantation Department, Hospital Clínic de Barcelona, ICNU, Barcelona, Spain.
³ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
⁴ Department of Medicine, University of Barcelona, Barcelona, Spain.
⁵ Pharmacy Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
⁶ Fundació i Institut de Recerca Josep Carreras contra la leucèmia (Campus Clínic), Barcelona, Spain.
⁷ Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain. queralt.salas87@outlook.es.
⁸ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. queralt.salas87@outlook.es.

Marta Gómez-Hernando et al. Bone Marrow Transplant. 2023 Feb.

. 2023 Feb;58(2):212-214.

doi: 10.1038/s41409-022-01864-7. Epub 2022 Nov 5.

¹ Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.
² Clinical Nephrology Section, Nephrology and Renal Transplantation Department, Hospital Clínic de Barcelona, ICNU, Barcelona, Spain.
³ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
⁴ Department of Medicine, University of Barcelona, Barcelona, Spain.
⁵ Pharmacy Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
⁶ Fundació i Institut de Recerca Josep Carreras contra la leucèmia (Campus Clínic), Barcelona, Spain.
⁷ Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain. queralt.salas87@outlook.es.
⁸ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. queralt.salas87@outlook.es.

No abstract available

References

1. Salas MQ, Charry P, Pedraza A, Martinez-Cibrian N, Solano MT, Domenech A, et al. PTCY and Tacrolimus for GVHD prevention for older adults undergoing HLA-matched sibling and unrelated donor AlloHCT. Transpl Cell Ther. 2022;28:489 e1–e9. - DOI
1. Nunes NS, Kanakry CG. Mechanisms of Graft-versus-Host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol. 2019;10:2668. - DOI
1. Clifton K, Barnett C, Martinez A, Karuturi M, Saleem S, Litton J. Severe hyponatremia following cyclophosphamide infusion in breast cancer patients. Breast J. 2018;24:691–2. - DOI
1. Bruining DM, van Roon EN, de Graaf H, Hoogendoorn M. Cyclophosphamide-induced symptomatic hyponatraemia. Neth J Med. 2011;69:192–5.
1. Lee YC, Park JS, Lee CH, Bae SC, Kim IS, Kang CM, et al. Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide. Nephrol Dial Transpl. 2010;25:1520–4. - DOI